Composition of the NRTI back-bone of the regimen started after the discontinuation of tenofovir (rows), according to the initial third drug (columns)–All tenofovir discontinuations.
To evaluate 96-week virologic, immunologic, resistance and metabolic outcomes of bictegravir/emtricitabine/tenofovir alafenamide fumarate (BIC/FTC/TAF) in antiretroviral therapy (ART)-naïve people li
